X4 Pharmaceuticals, Inc. — Q3 2019 Form 10-Q
Business context and period. This unaudited filing covers the quarter and nine months ended September 30, 2019. X4 is a clinical-stage biopharmaceutical company developing treatments for rare diseases, led by mavorixafor (X4P-001), a CXCR4 antagonist. The March 2019 merger with Arsanis was accounted for as a reverse merger, with X4 as the accounting acquirer; prior-period operating results therefore primarily reflect X4, not the combined company. X4 had no product-sales revenue.
Key financial metrics
| Metric | Q3 2019 | Q3 2018 | Nine months 2019 | Nine months 2018 |
|---|---|---|---|---|
| Revenue | None reported | None reported | None reported | None reported |
| Research and development expense | $8.6 million | $6.2 million | $23.1 million | $15.7 million |
| General and administrative expense | $4.4 million | $2.4 million | $13.7 million | $5.4 million |
| Net loss | $17.7 million | $8.6 million | $42.0 million | $22.0 million |
| Net loss per share | $1.22 | $20.39 | $4.31 | $52.92 |
| Operating cash used | Not stated for quarter | Not stated for quarter | $38.8 million | $18.7 million |
As of September 30, 2019, cash and cash equivalents were $76.3 million, restricted cash was $0.8 million, and total current assets were $79.2 million. Total liabilities were $30.4 million, including $20.0 million of long-term debt and $3.0 million of lease liabilities. There was no current portion of long-term debt reported. No meaningful operating margin comparison is available because the company reported no revenue.
Changes versus the prior comparable period
- Q3 operating expenses rose $8.4 million year over year; nine-month expenses increased $19.8 million. R&D growth reflected mavorixafor’s progression into Phase 3 and additional personnel and research-site costs; G&A rose with merger, public-company, legal, and staffing costs.
- Net loss increased by $9.1 million in Q3 and $20.0 million for the nine-month period. Comparisons are affected by the merger and by changes in the company’s capital structure.
- Nine-month operating cash use more than doubled. Cash, cash equivalents, and restricted cash nevertheless increased to $77.0 million, primarily reflecting the April equity offering, merger cash acquired, and financing activity.
- In April, X4 raised $79.3 million net from an offering of common stock and warrants. In June, it refinanced its Hercules debt, ending the quarter with $20.0 million principal outstanding. The FFG loans were repaid in September.
Outlook, commentary, risks, and unusual items
- Management expected existing cash and cash equivalents to fund operating expenses, capital expenditures, and debt service for at least 12 months from the November 7, 2019 financial-statement issuance date. It said longer-term viability depends on raising additional capital; the estimate relies on assumptions and cash could be exhausted sooner than expected.
- X4 initiated the pivotal 52-week Phase 3 4WHIM trial in June 2019 and expected top-line data in 2021. It expected SCN trial data in mid-2020 and planned to begin a WM Phase 1b trial in Q4 2019, with data expected in the second half of 2020. These are management expectations, not guarantees.
- Management expected R&D spending to increase as clinical programs advance, alongside further G&A costs associated with growth and public-company operations. It reported positive Phase 2a results for mavorixafor plus axitinib in advanced clear-cell renal cell carcinoma and said it intended to explore strategic partnering for oncology development. Mavorixafor also received European orphan-drug designation for WHIM syndrome.
- A $4.0 million Q3 loss on transfer of acquired IPR&D followed licensing the acquired ASN programs to third parties; X4 reported no continuing R&D involvement in those programs. It received $0.9 million in upfront fees and may receive contingent future fees. A $566,000 debt-extinguishment loss was recorded when FFG loans were repaid.
- Key risks include clinical and regulatory uncertainty, the need for further financing, dependence on third-party manufacturers, and intellectual-property and execution risks. Hercules debt is secured by substantially all assets other than intellectual property, including proceeds from IP dispositions; the agreement imposes liquidity and other covenants. X4 reported no material legal proceedings and no material changes to previously disclosed risk factors.
Important facts for investors to verify
- Whether the 4WHIM, SCN, and planned WM trials meet enrollment, timing, safety, and efficacy expectations, and whether management’s projected data dates remain current.
- Cash burn and runway against the 12-month funding estimate, including restricted cash and the Hercules lender-accessible cash and liquidity requirements.
- Debt terms and obligations: $20.0 million Hercules principal, interest rate, fees, covenants, and the scheduled principal-repayment period beginning in 2022.
- Potential dilution: the filing reported 6.49 million outstanding warrants and 1.27 million outstanding options at September 30, 2019; exercise and dilution depend on applicable terms and conditions.
- Whether future contingent payments from the out-licensed programs or Abbisko agreement are achieved; the filing did not recognize material milestone consideration as revenue at quarter-end.